Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Celldex Therapeutics Inc CLDX

Healthcare Biotechnology
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its Barzolvolimab, a monoclonal antibody... see more

Recent & Breaking News (NDAQ:CLDX)

Mid-Afternoon Market Update: Dow Drops 250 Points; Biostar Pharmaceuticals Shares Spike Higher

Benzinga.com  October 11, 2016

Phase 2 Study of Single-agent Glembatumumab Vedotin in Patients with Checkpoint-Refractory Metastatic Melanoma Meets Primary Overall Response Endpoint and Demonstrates Clinically Meaningful Duration of Response

GlobeNewswire October 9, 2016

Mid-Afternoon Market Update: Dow Drops More Than 100 Points; Summit Therapeutics Shares Spike Higher

Benzinga.com  October 4, 2016

The Market In 5 Minutes: A Three-Decade Low For The Pound

Benzinga.com  October 4, 2016

15 Stocks Moving In Tuesday's Pre-Market Session

Benzinga.com  October 4, 2016

Celldex Therapeutics to Present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable

GlobeNewswire September 23, 2016

Drug Price Hike Concerns Spill Over Into Other Pharma Stocks

Benzinga.com  August 24, 2016

Celldex Appoints Elizabeth Crowley as Chief Product Development Officer

GlobeNewswire August 11, 2016

Celldex Reports Second Quarter 2016 Results

GlobeNewswire August 8, 2016

Celldex to Report Second Quarter 2016 Financial Results and Host Corporate 2016 Objectives Update Call

GlobeNewswire August 2, 2016

ARMOUR Residential REIT, Inc. Reports Financial Results for the Quarter Ended June 30, 2016

GlobeNewswire August 2, 2016

Celldex Therapeutics Initiates Phase 1/2 Clinical Trial of New Product Candidate CDX-014 in Advanced Renal Cell Carcinoma

GlobeNewswire July 11, 2016

Celldex Therapeutics to Participate in the Cantor Fitzgerald 2nd Annual Healthcare Conference

GlobeNewswire July 7, 2016

7 Stocks Moving In Thursday's After-Hours Session: Oracle, Smith & Wesson And More

Benzinga.com  June 16, 2016

Biotechnology Stocks in Motion -- Celldex Therapeutics, Medivation, Opko Health, and ACADIA Pharma

PR Newswire June 7, 2016

Celldex Reports First Quarter 2016 Results

GlobeNewswire May 5, 2016

These Stocks Are Starting To Catch Wall Street's Attention

Accesswire April 29, 2016

Celldex Therapeutics Initiates Phase 1/2 Study of Glembatumumab Vedotin in Squamous Cell Lung Cancer

GlobeNewswire April 27, 2016

4 Biotech Stocks to Buy at Beaten Down Prices

Accesswire April 27, 2016

Celldex Therapeutics Presents Data Supporting the Clinical Development of Glembatumumab Vedotin and the Preclinical CD40 Program at the AACR Annual Meeting 2016

GlobeNewswire April 20, 2016